$INBP
INTEGRATED BIOPHARMA INC

2019 Q2 Form 10-K Financial Statement

#000143774920020123 Filed on September 23, 2020

View on sec.gov

Income Statement

Concept 2019 Q2 2019 2018 Q2
Revenue $13.58M $49.98M $12.57M
YoY Change 8.07% 14.34% 11.73%
Cost Of Revenue $12.01M $43.76M $11.10M
YoY Change 8.15% 13.0% 16.35%
Gross Profit $1.579M $6.222M $1.470M
YoY Change 7.41% 24.74% -14.04%
Gross Profit Margin 11.62% 12.45% 11.69%
Selling, General & Admin $1.005M $3.518M $840.0K
YoY Change 19.64% 6.8% -4.55%
% of Gross Profit 63.65% 56.54% 57.14%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $87.00K $321.0K $90.00K
YoY Change -3.33% -7.76% 0.0%
% of Gross Profit 5.51% 5.16% 6.12%
Operating Expenses $1.005M $3.518M $840.0K
YoY Change 19.64% 6.8% -3.45%
Operating Profit $574.0K $2.704M $630.0K
YoY Change -8.89% 59.62% -25.0%
Interest Expense -$67.00K $630.0K $140.0K
YoY Change -147.86% -31.97% -800.0%
% of Operating Profit -11.67% 23.3% 22.22%
Other Income/Expense, Net -$50.00K -$662.0K $90.00K
YoY Change -155.56% -3.92%
Pretax Income $457.0K $2.042M $750.0K
YoY Change -39.07% 103.18% -3.85%
Income Tax $97.00K $354.0K -$10.00K
% Of Pretax Income 21.23% 17.34% -1.33%
Net Earnings $360.0K $1.688M $820.0K
YoY Change -56.1% 148.6% -46.75%
Net Earnings / Revenue 2.65% 3.38% 6.52%
Basic Earnings Per Share $0.06
Diluted Earnings Per Share $11.83K $0.06 $14.17K
COMMON SHARES
Basic Shares Outstanding 28.93M
Diluted Shares Outstanding 29.59M

Balance Sheet

Concept 2019 Q2 2019 2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $475.0K $475.0K $230.0K
YoY Change 106.52% 108.33% -61.67%
Cash & Equivalents $475.0K $228.0K
Short-Term Investments
Other Short-Term Assets $346.0K $346.0K $493.0K
YoY Change -29.82% -29.82% -34.62%
Inventory $8.819M $8.819M $7.741M
Prepaid Expenses
Receivables $4.439M $4.439M $3.796M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $14.08M $14.08M $12.26M
YoY Change 14.86% 14.86% -2.33%
LONG-TERM ASSETS
Property, Plant & Equipment $1.778M $5.062M $1.778M
YoY Change 0.0% 206.6% 11.06%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $649.0K $649.0K $660.0K
YoY Change -1.67% -1.52% -36.54%
Total Long-Term Assets $5.711M $5.711M $2.310M
YoY Change 147.23% 147.23% -12.67%
TOTAL ASSETS
Total Short-Term Assets $14.08M $14.08M $12.26M
Total Long-Term Assets $5.711M $5.711M $2.310M
Total Assets $19.79M $19.79M $14.57M
YoY Change 35.85% 35.85% -4.13%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.855M $3.855M $4.184M
YoY Change -7.86% -7.86% 0.17%
Accrued Expenses $1.617M $1.617M $1.060M
YoY Change 52.55% 52.55% -10.17%
Deferred Revenue
YoY Change
Short-Term Debt $5.834M $5.834M $4.890M
YoY Change 19.3% 19.21% 4.49%
Long-Term Debt Due $1.047M $1.047M $773.0K
YoY Change 35.45% -82.67% -30.86%
Total Short-Term Liabilities $12.35M $12.35M $16.18M
YoY Change -23.65% -23.65% 45.05%
LONG-TERM LIABILITIES
Long-Term Debt $2.722M $2.722M $3.624M
YoY Change -24.89% -24.89% -14.65%
Other Long-Term Liabilities $2.822M $2.822M $0.00
YoY Change -100.0%
Total Long-Term Liabilities $2.722M $5.544M $3.624M
YoY Change -24.89% 52.98% -14.65%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.35M $12.35M $16.18M
Total Long-Term Liabilities $2.722M $5.544M $3.624M
Total Liabilities $17.90M $17.90M $19.80M
YoY Change -9.63% -9.63% -6.25%
SHAREHOLDERS EQUITY
Retained Earnings -$48.26M -$49.95M
YoY Change -3.38% -1.34%
Common Stock $59.00K $42.00K
YoY Change 40.48% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost) $99.00K $99.00K
YoY Change 0.0% 0.0%
Treasury Stock Shares $34.90K $34.90K
Shareholders Equity $1.893M $1.893M -$5.236M
YoY Change
Total Liabilities & Shareholders Equity $19.79M $19.79M $14.57M
YoY Change 35.85% 35.85% -4.13%

Cashflow Statement

Concept 2019 Q2 2019 2018 Q2
OPERATING ACTIVITIES
Net Income $360.0K $1.688M $820.0K
YoY Change -56.1% 148.6% -46.75%
Depreciation, Depletion And Amortization $87.00K $321.0K $90.00K
YoY Change -3.33% -7.76% 0.0%
Cash From Operating Activities $627.0K $328.0K -$170.0K
YoY Change -468.82% -71.92% -79.27%
INVESTING ACTIVITIES
Capital Expenditures -$64.00K $414.0K -$30.00K
YoY Change 113.33% 67.61% 50.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 -$8.000K $0.00
YoY Change -260.0%
Cash From Investing Activities -$64.00K -$422.0K -$30.00K
YoY Change 113.33% 74.38% 50.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -519.0K 341.0K 370.0K
YoY Change -240.27% -141.08% -51.95%
NET CHANGE
Cash From Operating Activities 627.0K 328.0K -170.0K
Cash From Investing Activities -64.00K -422.0K -30.00K
Cash From Financing Activities -519.0K 341.0K 370.0K
Net Change In Cash 44.00K 247.0K 170.0K
YoY Change -74.12% 157.29% -342.86%
FREE CASH FLOW
Cash From Operating Activities $627.0K $328.0K -$170.0K
Capital Expenditures -$64.00K $414.0K -$30.00K
Free Cash Flow $691.0K -$86.00K -$140.0K
YoY Change -593.57% -109.34% -82.5%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 dei Amendment Flag
AmendmentFlag
false
CY2020 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2020 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2020 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020 dei Document Period End Date
DocumentPeriodEndDate
2020-06-30
CY2020 dei Document Type
DocumentType
10-K
CY2020 dei Entity Central Index Key
EntityCentralIndexKey
0001016504
CY2020Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
29645943
CY2020 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2020 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2019Q4 dei Entity Public Float
EntityPublicFloat
2301741
CY2020 dei Entity Registrant Name
EntityRegistrantName
INTEGRATED BIOPHARMA INC
CY2020 dei Entity Shell Company
EntityShellCompany
false
CY2020 dei Entity Small Business
EntitySmallBusiness
true
CY2020 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2020 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2019 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
48937000
CY2020 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
1639000
CY2019 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
2400000
CY2020 dei Security12g Title
Security12gTitle
Common Stock, $.002 par value per share
CY2020 dei Trading Symbol
TradingSymbol
inbp
CY2020 inbp Accretion On Embedded Derivative Feature
AccretionOnEmbeddedDerivativeFeature
CY2019 inbp Accretion On Embedded Derivative Feature
AccretionOnEmbeddedDerivativeFeature
3000
CY2020Q2 inbp Cost Method Investment Ownership Percentage
CostMethodInvestmentOwnershipPercentage
0.06
CY2020 inbp Effective Income Tax Rate Reconciliation Statutory Minimum Taxes Percent
EffectiveIncomeTaxRateReconciliationStatutoryMinimumTaxesPercent
0.025
CY2019 inbp Effective Income Tax Rate Reconciliation Statutory Minimum Taxes Percent
EffectiveIncomeTaxRateReconciliationStatutoryMinimumTaxesPercent
0.07
CY2020 inbp Finance Lease Expense
FinanceLeaseExpense
70000
CY2019 inbp Finance Lease Expense
FinanceLeaseExpense
109000
CY2020 inbp Gain From Assets Contribution To Investment
GainFromAssetsContributionToInvestment
CY2019 inbp Gain From Assets Contribution To Investment
GainFromAssetsContributionToInvestment
-97000
CY2020 inbp Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-462000
CY2019 inbp Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-454000
CY2020Q2 inbp Lease Commitment Amount
LeaseCommitmentAmount
3141000
CY2019Q2 inbp Lease Commitment Amount
LeaseCommitmentAmount
3719000
CY2020Q2 inbp Lessee Operating Lease And Finance Lease Liability Payments Due
LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDue
3218000
CY2020Q2 inbp Lessee Operating Lease And Finance Lease Liability Payments Due After Year Six
LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueAfterYearSix
280000
CY2020Q2 inbp Lessee Operating Lease And Finance Lease Liability Payments Due Year Five
LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFive
564000
CY2020Q2 inbp Lessee Operating Lease And Finance Lease Liability Payments Due Year Four
LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFour
567000
CY2020Q2 inbp Lessee Operating Lease And Finance Lease Liability Payments Due Year One
LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearOne
664000
CY2020Q2 inbp Lessee Operating Lease And Finance Lease Liability Payments Due Year Three
LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearThree
567000
CY2020Q2 inbp Lessee Operating Lease And Finance Lease Liability Payments Due Year Two
LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearTwo
576000
CY2020Q2 inbp Lessee Operating Lease And Finance Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseAndFinanceLeaseLiabilityUndiscountedExcessAmount
313000
CY2020Q2 inbp Operating Lease And Finance Lease Liability
OperatingLeaseAndFinanceLeaseLiability
2905000
CY2020 inbp Operating Lease Interest Expense
OperatingLeaseInterestExpense
13000
CY2019 inbp Operating Lease Interest Expense
OperatingLeaseInterestExpense
18000
CY2020 inbp Operating Lease Rightofuse Asset Amortization
OperatingLeaseRightofuseAssetAmortization
460000
CY2019 inbp Operating Lease Rightofuse Asset Amortization
OperatingLeaseRightofuseAssetAmortization
453000
CY2020 inbp Repayments Of Long Term Capital Lease Obligations Including Interest
RepaymentsOfLongTermCapitalLeaseObligationsIncludingInterest
194000
CY2019 inbp Repayments Of Long Term Capital Lease Obligations Including Interest
RepaymentsOfLongTermCapitalLeaseObligationsIncludingInterest
233000
CY2020Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
4358000
CY2019Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3855000
CY2020Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5507000
CY2019Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4439000
CY2020Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1384000
CY2019Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1147000
CY2020Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7312000
CY2019Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7040000
CY2019Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
84000
CY2020 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
CY2020Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
50263000
CY2019Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
50197000
CY2019 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
144000
CY2020 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
59000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
59000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
144000
CY2020Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
99000
CY2019 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
3000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
2562000
CY2020Q2 us-gaap Assets
Assets
22944000
CY2019Q2 us-gaap Assets
Assets
19790000
CY2020Q2 us-gaap Assets Current
AssetsCurrent
16461000
CY2019Q2 us-gaap Assets Current
AssetsCurrent
14079000
CY2020 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
16000
CY2019 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
402000
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
475000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
475000
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
228000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
402000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-73000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
247000
CY2020Q2 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2020Q2 us-gaap Cash Uninsured Amount
CashUninsuredAmount
70000
CY2020Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.002
CY2019Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.002
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29680843
CY2019Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29600843
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29645943
CY2019Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29565943
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
59000
CY2019Q2 us-gaap Common Stock Value
CommonStockValue
59000
CY2020 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
46042000
CY2019 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
43755000
CY2020 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-40000
CY2019 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
36000
CY2020 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
369000
CY2019 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
287000
CY2020 us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
549000
CY2019 us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
621000
CY2020Q2 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
39000
CY2019Q2 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
50000
CY2020Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
1883000
CY2019Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
534000
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1349000
CY2019 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
33000
CY2020Q2 us-gaap Deferred Tax Assets Capital Loss Carryforwards
DeferredTaxAssetsCapitalLossCarryforwards
258000
CY2019Q2 us-gaap Deferred Tax Assets Capital Loss Carryforwards
DeferredTaxAssetsCapitalLossCarryforwards
16000
CY2020Q2 us-gaap Deferred Tax Assets Derivative Instruments
DeferredTaxAssetsDerivativeInstruments
34000
CY2019Q2 us-gaap Deferred Tax Assets Derivative Instruments
DeferredTaxAssetsDerivativeInstruments
31000
CY2020Q2 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
142000
CY2019Q2 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
104000
CY2020Q2 us-gaap Deferred Tax Assets Investments
DeferredTaxAssetsInvestments
254000
CY2019Q2 us-gaap Deferred Tax Assets Investments
DeferredTaxAssetsInvestments
512000
CY2020Q2 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
1883000
CY2019Q2 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
534000
CY2020Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
7047000
CY2019Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
7642000
CY2020Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
5648000
CY2019Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
7546000
CY2020Q2 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
204000
CY2019Q2 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
225000
CY2020 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
68000
CY2019 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
69000
CY2020Q2 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
80000
CY2019Q2 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
115000
CY2020 us-gaap Depreciation
Depreciation
312000
CY2019 us-gaap Depreciation
Depreciation
288000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
312000
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
321000
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.14
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.06
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.13
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.06
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.33
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.173
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.69
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.207
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.001
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.01
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.029
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.02
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.095
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.07
CY2020 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
13000
CY2019 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
18000
CY2020Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
75000
CY2019Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
269000
CY2020Q2 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
77000
CY2020Q2 us-gaap Finance Lease Liability Payments Due After Year Five
FinanceLeaseLiabilityPaymentsDueAfterYearFive
CY2020Q2 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
77000
CY2020Q2 us-gaap Finance Lease Liability Payments Due Year Five
FinanceLeaseLiabilityPaymentsDueYearFive
CY2020Q2 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
CY2020Q2 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
CY2020Q2 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
CY2020Q2 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
2000
CY2020 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
57000
CY2019 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
91000
CY2020 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
4000
CY2019 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
CY2020 us-gaap Gross Profit
GrossProfit
6727000
CY2019 us-gaap Gross Profit
GrossProfit
6222000
CY2019 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2020 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
3088000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
2042000
CY2020Q2 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2019Q2 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1020000
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
354000
CY2019 us-gaap Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability
IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
23000
CY2020 us-gaap Income Taxes Paid
IncomeTaxesPaid
384000
CY2019 us-gaap Income Taxes Paid
IncomeTaxesPaid
264000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
487000
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-329000
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1082000
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
593000
CY2020 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
22000
CY2019 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
49000
CY2020 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1282000
CY2019 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1077000
CY2020 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
237000
CY2019 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
96000
CY2020 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
7000
CY2019 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
73000
CY2019 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
8230769
CY2020 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1584995
CY2019 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
656055
CY2020 us-gaap Interest Expense
InterestExpense
397000
CY2019 us-gaap Interest Expense
InterestExpense
630000
CY2020 us-gaap Interest Expense Lessee Assets Under Capital Lease
InterestExpenseLesseeAssetsUnderCapitalLease
13000
CY2019 us-gaap Interest Expense Lessee Assets Under Capital Lease
InterestExpenseLesseeAssetsUnderCapitalLease
19000
CY2020 us-gaap Interest Expense Other
InterestExpenseOther
26000
CY2019 us-gaap Interest Expense Other
InterestExpenseOther
24000
CY2020 us-gaap Interest Expense Subordinated Notes And Debentures
InterestExpenseSubordinatedNotesAndDebentures
22000
CY2019 us-gaap Interest Expense Subordinated Notes And Debentures
InterestExpenseSubordinatedNotesAndDebentures
55000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
367000
CY2019 us-gaap Interest Paid Net
InterestPaidNet
629000
CY2020Q2 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
19000
CY2019Q2 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
13000
CY2020Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
879000
CY2019Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1944000
CY2020Q2 us-gaap Inventory Net
InventoryNet
10101000
CY2019Q2 us-gaap Inventory Net
InventoryNet
8819000
CY2020Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
6610000
CY2019Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
4550000
CY2020Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
2612000
CY2019Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
2325000
CY2020Q2 us-gaap Investment Owned At Fair Value
InvestmentOwnedAtFairValue
134000
CY2019Q2 us-gaap Investment Owned At Fair Value
InvestmentOwnedAtFairValue
84000
CY2020Q2 us-gaap Liabilities
Liabilities
16877000
CY2019Q2 us-gaap Liabilities
Liabilities
17897000
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
22944000
CY2019Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19790000
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
13099000
CY2019Q2 us-gaap Liabilities Current
LiabilitiesCurrent
12353000
CY2019Q2 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2020Q2 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2020Q2 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
4046000
CY2019Q2 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
5834000
CY2020Q2 us-gaap Long Term Debt
LongTermDebt
8344000
CY2019Q2 us-gaap Long Term Debt
LongTermDebt
9653000
CY2020Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
2823000
CY2019Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
1047000
CY2020Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1436000
CY2019Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2722000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1302000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
341000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-110000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-422000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1339000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
328000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
4108000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
1688000
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-171000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
2704000
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
670000
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
675000
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
488000
CY2019Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
470000
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2342000
CY2019Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2822000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
657000
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-662000
CY2020 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
3259000
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
657000
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2824000
CY2019Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3284000
CY2020Q2 us-gaap Other Assets Current
OtherAssetsCurrent
451000
CY2019Q2 us-gaap Other Assets Current
OtherAssetsCurrent
346000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
51000
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-9000
CY2020 us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
CY2019 us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
8000
CY2020 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
230000
CY2019 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
414000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
214000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
414000
CY2020 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:18pt;margin-right:0pt;margin-top:0pt;text-align:justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Reclassifications. </div></div>Certain prior year amounts have been reclassified to conform to the current year presentation.</div></div></div></div>
CY2020 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
47213000
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.09
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0.14
CY2019 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
CY2020 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
3000
CY2019 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
7000
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
24000
CY2019 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
47997000
CY2020 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
194000
CY2020 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
101000
CY2020 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
40000
CY2019 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
38000
CY2020Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9008000
CY2019Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8818000
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1696000
CY2019Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1778000
CY2020 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
15000
CY2019 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-50000
CY2020 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
72000
CY2019 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
CY2020 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
49001000
CY2019 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
233000
CY2020 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
966000
CY2019 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
3023000
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-44156000
CY2019Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-48264000
CY2020 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
52769000
CY2019 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
49977000
CY2020 us-gaap Sale Leaseback Transaction Net Proceeds Financing Activities
SaleLeasebackTransactionNetProceedsFinancingActivities
CY2019 us-gaap Sale Leaseback Transaction Net Proceeds Financing Activities
SaleLeasebackTransactionNetProceedsFinancingActivities
233000
CY2020 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3468000
CY2019 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3518000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
59000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
144000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P3Y
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
8799389
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2863800
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2875533
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.14
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.16
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
343250
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
200000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
17500
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
137500
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1883000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2439250
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3761500
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3344000
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.29
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.16
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.16
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.12
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0.10
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.18
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.14
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.21
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2020 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
0.09
CY2020 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
0.25
CY2020Q2 us-gaap Share Price
SharePrice
0.21
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
846000
CY2019Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
256000
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y255D
CY2019 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
200000
CY2020 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
80000
CY2019 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
5273000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
24000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
6067000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
1893000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
-5236000
CY2020Q2 us-gaap Treasury Stock Shares
TreasuryStockShares
34900
CY2019Q2 us-gaap Treasury Stock Shares
TreasuryStockShares
34900
CY2020Q2 us-gaap Treasury Stock Value
TreasuryStockValue
99000
CY2019Q2 us-gaap Treasury Stock Value
TreasuryStockValue
99000
CY2020 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
103000
CY2019 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-23000
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:18pt;margin-right:0pt;margin-top:0pt;text-align:justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Use of Estimates.</div></div> The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are <div style="display: inline; font-style: italic; font: inherit;">not</div> readily apparent from other sources. The most significant estimates include:</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:18pt;margin-right:0pt;margin-top:0pt;text-align:justify;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:18pt;margin-right:0pt;margin-top:0pt;text-align:justify;">&#x25cf;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;sales returns and allowances;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:18pt;margin-right:0pt;margin-top:0pt;text-align:justify;">&#x25cf;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;allowance for doubtful accounts;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:18pt;margin-right:0pt;margin-top:0pt;text-align:justify;">&#x25cf;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;inventory valuation;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:18pt;margin-right:0pt;margin-top:0pt;text-align:justify;">&#x25cf;&nbsp; &nbsp; &nbsp;valuation and recoverability of long-lived assets;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:18pt;margin-right:0pt;margin-top:0pt;text-align:justify;">&#x25cf;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;income taxes and valuation allowance on deferred income taxes, and;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:18pt;margin-right:0pt;margin-top:0pt;text-align:justify;">&#x25cf;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;accruals for, and the probability of, the outcome of any current litigation.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:18pt;margin-right:0pt;margin-top:0pt;text-align:justify;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:18pt;margin-right:0pt;margin-top:0pt;text-align:justify;">On a continual basis, management reviews its estimates utilizing currently available information, changes in facts and circumstances, historical experience and reasonable assumptions. After such reviews, and if deemed appropriate, those estimates are adjusted accordingly. Actual results could differ from those estimates.</div></div></div></div>
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-1898000
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-590000
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31157250
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29586550
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29572255
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28930495

Files In Submission

Name View Source Status
0001437749-20-020123-index-headers.html Edgar Link pending
0001437749-20-020123-index.html Edgar Link pending
0001437749-20-020123.txt Edgar Link pending
0001437749-20-020123-xbrl.zip Edgar Link pending
ex_202526.htm Edgar Link pending
ex_202527.htm Edgar Link pending
ex_202528.htm Edgar Link pending
ex_202529.htm Edgar Link pending
ex_202530.htm Edgar Link pending
ex_202531.htm Edgar Link pending
ex_204539.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
inbp-20200630.xml Edgar Link completed
inbp-20200630.xsd Edgar Link pending
inbp-20200630_cal.xml Edgar Link unprocessable
inbp-20200630_def.xml Edgar Link unprocessable
inbp-20200630_lab.xml Edgar Link unprocessable
inbp-20200630_pre.xml Edgar Link unprocessable
inbp20200630_10k.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending